4DMT's Ixo-vec Gene Therapy for nAMD Shows Progress in LUNA Phase 2 Trial
ByAinvest
Thursday, Dec 4, 2025 4:39 pm ET1min read
ADVM--
The article discusses the clinical progress of the LUNA Phase 2 trial for Ixo-vec gene therapy in treating nAMD. The trial has shown promising results, with 71% of patients achieving a 12-week stable or improved visual acuity, and 47% achieving a 24-week stable or improved visual acuity. The study has also shown a favorable safety profile, with only mild or moderate ocular and systemic adverse events. The author highlights the potential of Ixo-vec gene therapy to provide a long-term treatment option for patients with nAMD.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet